BioNTech (Germany) Performance
| 22UA Stock | EUR 93.80 1.60 1.74% |
BioNTech has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.18, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning BioNTech are expected to decrease at a much lower rate. During the bear market, BioNTech is likely to outperform the market. BioNTech SE right now shows a risk of 2.8%. Please confirm BioNTech SE downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if BioNTech SE will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, BioNTech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Ex Dividend Date 2022-06-02 |
1 | Is BioNTech SE Depositary Receipt stock a top pick in earnings season - July 2025 Closing Moves Stepwise Entry and Exit Trade Signals - newser.com | 11/18/2025 |
2 | BioNTech Advances with CureVac Exchange Offer Approval - TipRanks | 11/26/2025 |
3 | Analysts Offer Insights on Healthcare Companies Nano-X Imaging , Edgewise Therapeutics and BioNTech SE - The Globe and Mail | 12/05/2025 |
4 | BMO Capital Keeps Their Buy Rating on BioNTech SE - The Globe and Mail | 12/11/2025 |
5 | Aug Selloffs What margin trends mean for BioNTech SE Depositary Receipt stock - July 2025 Snapshot Capital Efficient Trade Techniques - moha.gov.vn | 01/13/2026 |
6 | What to Expect From Pfizers Non-Oncology Business in Q4 - Zacks Investment Research | 01/19/2026 |
7 | BioNTech Soars 11.8 percent Is Further Upside Left in the Stock - Nasdaq | 01/22/2026 |
8 | BioNTech SEs Price Is Right But Growth Is Lacking After Shares Rocket 26 percent - simplywall.st | 01/28/2026 |
9 | Leerink downgrades BioNTech to market perform after 24 percent share rally - Investing.com | 02/02/2026 |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 9,210 in BioNTech SE on November 8, 2025 and sell it today you would earn a total of 170.00 from holding BioNTech SE or generate 1.85% return on investment over 90 days. BioNTech SE is generating 0.0693% of daily returns assuming 2.8043% volatility of returns over the 90 days investment horizon. Simply put, 25% of all stocks have less volatile historical return distribution than BioNTech, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioNTech Target Price Odds to finish over Current Price
The tendency of BioNTech Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 93.80 | 90 days | 93.80 | about 17.53 |
Based on a normal probability distribution, the odds of BioNTech to move above the current price in 90 days from now is about 17.53 (This BioNTech SE probability density function shows the probability of BioNTech Stock to fall within a particular range of prices over 90 days) .
BioNTech Price Density |
| Price |
Predictive Modules for BioNTech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioNTech SE. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioNTech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioNTech is not an exception. The market had few large corrections towards the BioNTech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioNTech SE, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioNTech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 6.16 | |
Ir | Information ratio | 0.02 |
BioNTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioNTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioNTech SE can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 2.75 B. Net Loss for the year was (665.3 M) with profit before overhead, payroll, taxes, and interest of 2.6 B. | |
| About 57.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Leerink downgrades BioNTech to market perform after 24 percent share rally - Investing.com |
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.0304 | ||||
| Return On Asset | -0.023 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 8.83 B | ||||
| Shares Outstanding | 250.93 M | ||||
| Price To Earning | 45.99 X | ||||
| Price To Book | 1.27 X | ||||
| Price To Sales | 7.18 X | ||||
| Revenue | 2.75 B | ||||
| Gross Profit | 2.6 B | ||||
| EBITDA | (467.8 M) | ||||
| Net Income | (665.3 M) | ||||
| Cash And Equivalents | 914.9 M | ||||
| Cash Per Share | 3.75 X | ||||
| Total Debt | 39.5 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 2.67 X | ||||
| Book Value Per Share | 76.84 X | ||||
| Cash Flow From Operations | 207.7 M | ||||
| Earnings Per Share | (2.39) X | ||||
| Market Capitalization | 22.63 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 19.1 B | ||||
| Working Capital | 16.28 B | ||||
About BioNTech Performance
By analyzing BioNTech's fundamental ratios, stakeholders can gain valuable insights into BioNTech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 171.97 | 180.57 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 2.75 B. Net Loss for the year was (665.3 M) with profit before overhead, payroll, taxes, and interest of 2.6 B. | |
| About 57.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Leerink downgrades BioNTech to market perform after 24 percent share rally - Investing.com |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |